Kian Lim is an Oncology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 Barnes West Dr
Div Im Medical Oncology, Mob #2
Saint Louis, MO 631416287
Telephone
800-647-2098Provider last certified this registry record 18 May 2022.
Clinical trials
- Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Sponsor: Washington University School of Medicine
- Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Sponsor: Washington University School of Medicine
- BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20221 payment
- Merck Sharp & Dohme LLCProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
48.6%Other antiemetics29.3%Fosaprepitant100%Part B, office-administered≥15 patientsAnticholinergic10.8%Atropine sulfate99%Dicyclomine Hcl1%Part D + Part B<11 patients+ 9 more classes in this area
Cancer & immunology
40.3%Microtubule Inhibitor34.7%Paclitaxel protein-bound particles100%Part B, office-administered≥11 patientsNucleoside Metabolic Inhibitor3.9%Gemcitabine hydrochloride56%Fluorouracil44%Part B, office-administered≥19 patients+ 2 more classes in this area
Sensory organs
5.3%Corticosteroid5.1%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B≥34 patientsFluoroquinolone Antibacterial0.2%Ciprofloxacin Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer
Washington University
FY2026$602,576R01CA262414 - Targeting tumor innate immune signaling in pancreatic cancer
Washington University
FY2026$398,522R01CA219697
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”